Project Grant HT94252410919
Award Date
8/15/24
Completion Date
8/15/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
This $961,118 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The Johns Hopkins University to target gut bacterial androgen production in order to reverse abiraterone resistance in metastatic prostate cancer. The 3-year award, beginning September 1, 2024, will enable the university to conduct innovative scientific studies aimed at developing treatments to improve health outcomes for military...
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
This $1,972,922.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by The Johns Hopkins University to therapeutically target TREM2-positive tumor-associated macrophages within the tumor microenvironment of lethal prostate cancer, with the goal of reducing health disparities. The project will run from July 1, 2025 to June 30, 2028. As a leading academic research...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $459,932 to The Johns Hopkins University to conduct research on "INTERROGATING CRIBRIFORM LESIONS TO UNCOVER MECHANISMS OF PROSTATE CANCER AGGRESSIVENESS AND METASTASIS". The university will perform advanced biomedical research focused on developing innovative approaches to the prevention, diagnosis, and treatment of...
This federal Project Grant award, ID HT94252410076, was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to The Johns Hopkins University. The $163,750 award, granted on February 1, 2024, will support research examining the influence of the gut microbiome on drug metabolism and treatment resistance in prostate cancer, with a completion date of January 31, 2026. As a leading research institution, The Johns Hopkins...
The Johns Hopkins University will provide research services totaling $1,216,646 under a Project Grant award from the Defense Health Agency. The award's stated purpose is to investigate the role of polyamine metabolism in advanced prostate cancer. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care. Specifically, the program aims to develop medical solutions for battlefield...
This $1,406,799 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research to develop real-time localization techniques using near-infrared fluorophores to guide robotic-assisted radical prostatectomy procedures. The 3-year award, running from August 1, 2024 to July 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research to improve surgical outcomes and...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $271,697 Project Grant to The Johns Hopkins University on Sep 1, 2024. The grant funds research to "TARGET GUT BACTERIAL ANDROGEN PRODUCTION TO REVERSE ABIRATERONE RESISTANCE IN METASTATIC PROSTATE CANCER". This research aims to develop new treatments for metastatic prostate cancer by investigating the role of gut bacteria in androgen production and resistance to certain cancer...